Clinical Trials Arena on MSN
Clinical trial statistics gets an AI-era overhaul
For decades, statistical analysis has remained one of clinical research's most manual processes. As AI reshapes drug ...
AI in clinical trials holds great promise for the entire drug development lifecycle. However, any new technology should ...
Morning Overview on MSN
158 Alzheimer’s drugs are now moving through trials, the deepest pipeline researchers have ever tracked
Researchers have documented 158 drugs in active Alzheimer’s disease clinical trials as of January 1, 2026, spread across 192 ...
Medable Inc., the leading technology platform for agentic clinical development, today announced its Digital Data Flow (DDF) Agent, which automatically transforms static clinical trial protocols into ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
For Europe to remain an attractive site for phase 3 research, he argued, regulatory predictability is paramount. El-Galaly ...
The US Food and Drug Administration (FDA) has finalized a guidance for industry on development of drugs and therapeutic biologics for treating eosinophilic esophagitis (EoE), a chronic, allergic ...
Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.
More flexibility in early-phase development for cell therapies is needed, a panel of US Food and Drug Administration (FDA) ...
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...
This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results